Lumexa Imaging Holdings, Inc.

What they do

Lumexa operates outpatient diagnostic imaging centers across the U.S., providing services such as advanced imaging (MRI, CT, etc.) to patients referred by physicians and health systems. The company partners with health systems and contracted radiology practices, and also operates joint ventures with key hospital partners. Revenue is generated per procedure, with a growing mix of advanced imaging services.

Revenue drivers

• Advanced outpatient imaging volume — Consolidated advanced outpatient volume grew 6.8% in Q2 2026, driving revenue growth; system-wide advanced volume grew 6.3%.
• Same-center volume growth — Same-center advanced outpatient volume grew 5.2% consolidated and 4.9% system-wide in Q2 2026, indicating organic demand strength.
• New center openings and joint ventures — The company announced four new imaging centers year-to-date and a joint venture with Hospital for Special Surgery, its second new JV in the past twelve months, expanding its footprint and revenue base.

Recent performance

For Q2 2026, Lumexa reported consolidated revenues of $264.2 million, up 5.1% from $251.4 million a year ago. Net income was $2.7 million, versus a net loss of $7.2 million in the prior-year quarter. Adjusted EBITDA was $56.4 million (21.4% margin), roughly flat versus $56.3 million (22.4% margin) last year. GAAP EPS was $0.03 per share, and Adjusted EPS was $0.20 per share.

Strategy

Management emphasizes expanding its health system partnerships and opening new imaging centers to drive growth. The company focuses on increasing the mix of advanced imaging procedures, which carry higher reimbursement. Lumexa also aims to capitalize on durable demand tailwinds and a large addressable market, while maintaining cost discipline despite fixed-cost structure. Recent JV with HSS represents a strategic move to deepen relationships with leading health systems.

Risks

• Referral dependence — Revenue depends heavily on referrals from physicians and healthcare providers; any decline could materially impact volumes.
• Fixed cost structure — Lower scan volumes would directly pressure profitability, as a large portion of costs are fixed.
• Radiologist staffing shortage — The company relies on hiring and retaining qualified radiologists and technologists, and faces nationwide shortages and rising labor costs.
• Reimbursement rate risk — Reductions in reimbursement rates from governmental or commercial payors could harm financial results, given the company's dependence on third-party reimbursement.

Outlook

Lumexa reiterated full-year 2026 consolidated revenue guidance of $1.045 billion to $1.097 billion. It narrowed Adjusted EBITDA guidance to $235 million to $241 million, with an unchanged midpoint of $238 million, including about $7 million of incremental public company costs. The company also reiterated Adjusted EPS guidance of $0.71 to $0.77 per share.